What are the indications for Osimertinib (Tagressa)?

Osimertinib is a targeted therapy drug mainly used to treat non-small cell lung cancer (NSCLC), especially those with advanced NSCLC patients with specific epidermal growth factor receptor (EGFR) gene mutations. The following are the main indications for osimertinib:

1.EGFRmutation-positive late-stage NSCLC: Osimertinib is mainly used to treat patients with EGFR late-stage NSCLC who are mutation-positive. These mutations often include specific variations in the EGFR gene, such as Del19 and L858R, which are overexpressed in tumor cells and promote tumor growth and spread.

2.EGFR T790MPositive advanced NSCLC: In addition to being a first-line treatment, osimertinib is also used to treat NSCLC patients who have been treated with other EGFR inhibitors, especially those with EGFR Patients with T790Mdrug resistance mutations. EGFR T790Mmutation is one of the common EGFR resistance mutations, and the use of osimertinib can effectively overcome this resistance.

3.EGFRmutation-positive NSCLC with brain metastases: Osimertinib is also used to treat patients with EGFR mutation-positive NSCLC, especially those with brain metastases. Because of its ability to penetrate the blood-brain barrier, osimertinib can control the growth and spread of brain metastases to a certain extent.

In general, osimertinib is mainly suitable for patients with advanced EGFR mutation-positive NSCLC, including first-line treatment and as an option for subsequent treatment. It can not only effectively control the growth and spread of tumors, but also improve patients' survival and quality of life. However, when treated with osimertinib, patients need to closely follow their doctor's instructions and undergo regular monitoring and evaluation to ensure optimal efficacy and safety of the drug.